Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable Unresectable or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary cancers who have previously undergone treatment with chemotherapy, surgery, photodynamic therapy, conventionally fractionated radiation treatment, or any combination of these therapies.
The purpose of this study is to evaluate stereotactic body radiation therapy (SBRT) for cancer of the pancreas.
- IRB Number: 1601638414 (IUSCC-0565)
- Research Study Identifier: TX6140
- Principal Investigator: Susannah Ellsworth, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required